![]() |
市場調查報告書
商品編碼
2024593
神經血管內彈簧圈市場報告:按產品類型、適應症、應用、最終用戶和地區分類(2026-2034 年)Neuroendovascular Coil Market Report by Product Type (Guglielmi Detachable Coils, Matrix Coils), Indication, Application, End User (Hospitals, Ambulatory Surgical Centers, Stroke Centers, and Others), and Region 2026-2034 |
||||||
2025年全球神經血管線圈市場規模達10.525億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到13.173億美元,2026年至2034年的複合年成長率為2.45%。
血管內彈簧圈栓塞術(NDC)是一種微創血管內治療方法,用於阻斷腦血管內的血流。它對於治療動脈瘤至關重要,動脈瘤是由於血管壁薄弱而形成的凸起。動脈瘤可能因壓力升高而破裂,導致腦出血。動脈瘤破裂的常見症狀包括突發性劇烈頭痛、噁心、嘔吐、視力Sumiya Co., Ltd.複視、癲癇發作。在NDC中,外科醫師會將可移除的鉑金彈簧圈密集地填充到動脈瘤內,這些彈簧圈可以促進血液凝固並降低動脈瘤外壁的壓力。由於NDC費用較低且能降低患者風險,因此在全球範圍內越來越受歡迎。
在神經血管栓塞技術方面,線圈的形狀、長度和生物活性均取得了多項進展。此外,顱內支架也取得了顯著進步,其部署和傳輸性能得到提升。外科醫生開始將顱內支架與線圈技術結合,以減輕動脈瘤治療和復發相關的併發症。此外,就術後併發症、治療效果和復健而言,血管內線圈栓塞術被認為是優於動脈瘤夾閉術的手術方法。除此之外,眾多市場參與者正致力於研發技術先進的產品。例如,2018年,強生醫療器材公司旗下的Serenovas推出了「Galaxy G3 Mini」栓塞線圈,該線圈採用不規則形狀設計,可填充腦動脈瘤周圍的空間。
IMARC Group最新發布的報告深入分析了全球神經血管線圈市場的各個關鍵面向。報告涵蓋了從宏觀市場概覽到微觀產業表現、近期趨勢、主要市場促進因素和挑戰、SWOT分析、波特五力分析以及價值鏈分析等各個層面。對於企業家、投資者、研究人員、顧問、商務策略以及所有對神經血管線圈市場感興趣或計劃進入該市場的人士而言,這份報告都是必讀之作。
The global neuroendovascular coil market size reached USD 1,052.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,317.3 Million by 2034, exhibiting a growth rate (CAGR) of 2.45% during 2026-2034.
Neuroendovascular coiling is a minimally invasive endovascular treatment which is performed to block the blood flow in a blood vessel in the brain. It is essential to treat an aneurysm, a bulge caused by weakness in the wall of a blood vessel, which can rupture due to rising pressure and bleed into the brain. The symptoms of a ruptured aneurysm generally include sudden onset of a severe headache, nausea, vomiting, blurred or double vision, and seizure. In neuroendovascular coiling, a surgeon tightly packs the aneurysm with detachable platinum coils that promote blood clotting and reduce pressure on the outer wall. Neuroendovascular coiling is becoming popular across the globe as it incurs less cost and lowers the risk for the patients.
Several advances have been made in the neuroendovascular coil technology in terms of shape, length and bioactivity. Besides this, significant progress has been made in intracranial stents to improve their deployment and delivery. Surgeons have started integrating intracranial stents with the coil technology to treat aneurysms and reduce issues related to recurrence. Moreover, endovascular coiling is being considered a better surgical technique than clipping regarding postoperative complications, favorable outcomes and rehabilitation. Other than this, various market players are investing in the introduction of technologically advanced products. For instance, in 2018, Cerenovus, a division of the Johnson & Johnson Medical Devices Companies, launched the Galaxy G3 Mini embolic coil which is designed to have an irregular shape to enable the device to fill open spaces in cerebral aneurysms.
IMARC Group's latest report provides a deep insight into the global neuroendovascular coil market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the neuroendovascular coil market in any manner.
The report has also analysed the competitive landscape of the market with some of the key players being Medtronic, Stryker Corporation, DePuy Synthes, Penumbra, Johnson & Johnson Services Inc., Terumo Corporation, Cardinal Health, Boston Scientific Corporation, Cook Medical Incorporated, Balt Extrusion, EndoShape, etc.